Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum
The Readout Loud
00:00
Biotex Oks
We need clinical data, we need to see stocks reacting well when clin trials succeed. And so far, you know, each aspect of that equation hasn't quite come together for bioteck rate. An we are expecting another pretty big catalus from a much bigger company fairly soon. Alnilums data in a disease called t tr amloidosis could go up forty % or down 50%.
Transcript
Play full episode
